Buy sermorelin peptide: the word doing the work
When people buy sermorelin peptide rather than searching for the name alone, the extra word is usually doing something specific: it separates the molecule from growth hormone in the searcher's mind, and it signals that they want to know what is actually in the vial. Both are the right instincts, and both have concrete answers.
The reason this matters more here than for most compounds is that a research vial names nothing. A pharmacy label states what the preparation contains and who made it. A vial with a lot number states neither. Everything you know about identity comes from a document you have to read yourself and reference data you have to compare it against.
We link one supplier and take a commission on purchases through it, as our affiliate disclosure page sets out. That is why this page hands you the verification numbers rather than an assurance that the vendor is trustworthy.
The identity target, in numbers you can check
Sermorelin is a synthetic twenty-nine amino acid peptide identical to the active N-terminal fragment of human growth hormone-releasing hormone, which is written GHRH(1-29) amide. The sequence is YADAIFTNSYRKVLGQLSARKLLQDIMSR, with a C-terminal amide rather than a free acid.
The numbers that make it checkable are the formula, C149H246N44O42S, and the molecular weight, 3357.9 g/mol. Those sit on PubChem CID 16132413, which returns the title Sermorelin alongside both values. Any certificate describing a materially different mass is describing a different molecule, and that is a comparison anybody can run in a minute.
The C-terminal amide is not a technicality worth skipping. It is part of the identity, and a free-acid version of the same sequence is a different compound with a different mass. When a certificate prints a sequence, read the terminus as carefully as the residues.
A secretagogue, which is not growth hormone
The question buyers ask most often is whether this is the same thing as HGH, and the answer is no. Sermorelin binds the growth hormone-releasing hormone receptor on the anterior pituitary and prompts the gland to release the body's own growth hormone. Recombinant growth hormone is the hormone itself, administered directly. Those are different molecules doing different jobs at different points in the same pathway.
That distinction is worth holding onto because it is the one most often blurred in marketing copy, where anything in this neighbourhood gets described as a growth hormone product. A secretagogue asks the pituitary to do something. Whether it does, and what follows if it does, are separate questions that a purchase does not answer.
It is also the distinction that explains the compound's actual history. The approved indications for the original product were paediatric growth hormone deficiency and pituitary diagnostics, and the diagnostic use follows directly from what a secretagogue is: you give it and you measure what the pituitary does. PubMed holds 332 papers mentioning the compound, three with it in the title, and none pairing it with anti-aging.
Four purchases sold as one category
Sermorelin, tesamorelin, ipamorelin and ibutamoren are routinely presented as interchangeable options in the same growth hormone conversation. They are not interchangeable, they act at different receptors, and their regulatory positions in the United States could hardly be further apart.
Tesamorelin is a stabilised GHRH analog and it is currently approved, marketed as Egrifta. That is a live approval rather than a historical one, which makes it the only member of this group with a current US label. Ipamorelin and ibutamoren act at the ghrelin receptor rather than the GHRH receptor, so they are not GHRH analogs at all despite sharing shelf space with them.
Their positions on FDA's bulk substances list diverge just as sharply. Ibutamoren mesylate carries a Category 2 listing under both 503A and 503B, the strongest listing of any compound this site covers. Ipamorelin acetate is listed under 503B, as are GHRP-2 and GHRP-6. Sermorelin appears in none of those sections, because it was already a component of an approved drug product.
| Compound | What it is | Where it acts | US position |
|---|---|---|---|
| Sermorelin | GHRH(1-29) amide, 29 residues, 3357.9 g/mol | GHRH receptor, anterior pituitary | Was a component of Geref, approved 1997, now discontinued, no current label |
| Tesamorelin | A stabilised GHRH analog | GHRH receptor | Currently approved, marketed as Egrifta |
| Ipamorelin | A different peptide sold into the same market | Ghrelin receptor, not the GHRH receptor | Category 2 listing under 503B |
| Ibutamoren (MK-677) | A growth hormone secretagogue, not a GHRH analog | Ghrelin receptor | Category 2 listing under both 503A and 503B |
Four compounds routinely sold as one category, with the positions that separate them.
How to confirm the vial holds it
The check runs in three steps and none of them require equipment. Find the lot number stamped on the vial. Open the certificate the seller published for that lot and confirm the numbers match. Then compare the identity data on the certificate against the reference values above.
Method matters as much as result at the second step. A certificate reporting purity by HPLC with ultraviolet detection alone has measured how much of something is present without confirming what it is. Look for mass spectrometry in the method line, because that is the part of the analysis that speaks to identity rather than quantity.
On the listing we link, that document is for lot 38-01260229. MZ Biolabs in Tucson, Arizona analysed it on 7 February 2026, signed on the thirteenth, using HPLC with ultraviolet and mass spectrometric detection across four detected peaks. We converted the sequence printed on it ourselves, and it resolves to exactly the canonical twenty-nine residue GHRH(1-29) amide. The right compound is described. Our supplier checklist works through the rest of the document.
What that certificate settled, and what it left open
It settled identity, which is the question this page exists to answer, and it settled two figures: 99.79% purity and 11.31 mg of material measured against a 10 mg label. The second is 13.1% over on that lot, which moves the effective price from $3.60 to $3.18 per milligram at the $36.00 checkout figure.
It left open the two assays that matter most for a powder that gets reconstituted. There is no endotoxin test on that certificate and no sterility test on it. FDA's stated concern for the peptides it did place in Category 2 is the risk for immunogenicity, attributed to the potential for aggregation and peptide-related impurities, and a purity figure does not reach that question.
Report all of it as a property of the lot rather than of the product. Lot 38-01260229 carries a certificate covering purity, quantity and identity. Another lot may carry more or less, and the only way to know is to read the document attached to the number on your own vial rather than the one a review page happened to look at.
The label a compounded fill would carry
Everything above is work you are doing because nothing on the vial does it for you. The comparison worth keeping in view is that for this compound, unlike most, a version exists where somebody else does it. A compounding pharmacy preparing sermorelin against a prescription produces a labelled preparation, and the label names what is in it.
That route exists because of a specific history. Sermorelin was sold as Geref by EMD Serono under NDA 019863 and NDA 020443, the therapeutic application approved on 26 September 1997 and both now discontinued, with FDA's record stating that the discontinuation was not for safety or effectiveness reasons. Section 503A permits a compounder to use a bulk substance that was a component of an approved drug product.
Two limits on what this page can do are worth stating. We verified identity from a published certificate and from public reference data, not by assaying a vial ourselves, and we can only speak to the lot that certificate names. Nobody can confirm from a photograph, a product description or a price that a particular vial holds GHRH(1-29), and no page claiming otherwise should be believed, including this one.
So the identity check on this page is not a substitute for a label. It is what you do in the absence of one, and it is genuinely worth doing, because the alternative is trusting a product description. If you would rather have the label, our guide to the prescription route sets out what it asks of you.